Changes

Jump to: navigation, search

Combining-Lamotrigine-Valproic acid

13 bytes added, 10:50, 23 April 2010
no edit summary
| add = valproic acid
| info =
* Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. Dose adaptation will be recommended for this combination.
| start =
* Reduce the lamotrigine dose by 50% of the general dose when combined with valproate. Start valproate at low dose and increase dose based on serum concentration slowly. <ref name=”medicatiebewaking”> Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002. </ref> <ref> {{Pubmed|8098122|Pisani at al, Interaction of lamotrigine with sodium valproate. Lancet. 1993 May 8;341(8854):1224.}}</ref>
| cave =
* Valproate can increase lamotrigine plasma levels significantly by inhibiting lamotrigine’s glucuronidation. This effect of valproate is dose-dependent.<ref name=”bazire”> Bazire S, Pshychotropic Psychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007. </ref>* Very slow titration of lamotrigine is recommended because reports of lamotrigine-related skin rashes. <ref> {{Pubmed|16225978|Chang CC at al, Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsych. Biol Psychiatry. 2006 Jan;30(1):147-50}}</ref>
}}
326
edits

Navigation menu